Resistance to rifampicin detected using phenotypic or genotypic methods, with or without resistance to other anti-TB drugs. It includes any resistance to rifampicin, whether monoresistance, multidrug resistance, polydrug resistance or extensive drug resistance

Resistance to rifampicin with or without resistance to other anti-TB drugs

Strain of M. tuberculosis is resistant to rifampicin detected using rapid diagnostic methods (phenotypic or genotypic), with or without resistance to other anti-TB drugs. It includes any resistance to rifampicin, in the form of monoresistance, multidrug resistance, polydrug resistance or extensive drug resistance

TB strains that are considered eligible for treatment with MDR-TB regimens. Rifampicin-resistant TB strains may be susceptible to isoniazid, or resistant to isoniazid (i.e. MDR-TB), or resistant to other medicines from the first-line group (poly-resistant) or from the second-line medicine group (e.g. XDR-TB)

Strains are considered not to be susceptible to rifampicin on the basis of DST and, as a result, are eligible for treatment with MDR-TB regimens. Rifampicin-resistant TB strains may be susceptible or resistant to isoniazid (i.e. MDR-TB), or resistant to other first-line TB medicines (polyresistant) or second-line TB medicines (e.g. extensively drug-resistant [XDR]-TB). In these guidelines and elsewhere, MDR-TB and RR-TB cases are often grouped together as MDR/RR-TB